RTI Surgical appoints Chad Croasdale as Chief Commercial Officer

RTI Surgical, a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, has announced the appointment of Chad Croasdale as Chief Commercial Officer.

Chad has more than 20 years of commercial and financial experience in the medical technology industry. As a member of RTI’s executive team, he will oversee the Company’s growth strategy and corporate development.

Prior to joining RTI, Chad served as President and Chief Commercial Officer of 270Surgical. Previously, he spent more than 18 years at Stryker in roles of increasing responsibility in sales and marketing, eventually serving as VP and General Manager of Stryker Communications, Endoscopy, where he oversaw the Communications Business Unit and drove commercial, sales, and R&D operations. Chad began his healthcare career as a physical therapist, specializing in sports medicine. He holds a BA in Psychology from Hobart College and an MS in Physical Therapy from Widener University.

Olivier Visa, President and Chief Executive Officer, RTI Surgical, said: “We are delighted to welcome Chad to RTI. His extensive experience in driving commercial success will be invaluable as we continue to establish ourselves as the CDMO partner of choice in regenerative medicine, leveraging our unique portfolio of xenograft and allograft biomaterials to improve patient outcomes.”

Chad Croasdale, Chief Commercial Officer, RTI Surgical, commented: “I am excited to join RTI Surgical, a company with a strong reputation for its commitment to quality, innovation and patients, and a clear strategy for growth. I look forward to working with the team and our OEM partners to develop biomaterials and expand our reach to even more patients.”

The post RTI Surgical appoints Chad Croasdale as Chief Commercial Officer appeared first on The Business Report of North Central Florida.